Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

The use of sacubitril/valsartan appears feasible and safe in recipients of left ventricular assist devices, reducing the need ...

Although findings from a large retrospective study supports these positive effects of taking a GLP-1, it’s unclear whether ...

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter, dragging the Swiss company's ...

The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, to reduce cardiovascular risk in type 2 diabetes ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Avoiding sleep drugs would reduce older Americans' lifetime rate of falls by nearly 9% and brain decline by 2%, among other ...

Rybelsus is now FDA-approved for managing cardiovascular health. Doctors say oral GLP-1s may reduce heart attack and stroke ...

On an overcast mid-October day, just inside the Third Avenue offices of We Heart Seattle, Executive Director Andrea Suarez ...

A new evidence review found patients infected with influenza or COVID-19 are significantly more likely to suffer a stroke or ...

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded ...

Certain medications, such as blood thinners, may interact with omega-3 supplements. Learn more about omega-3 interactions here.